Background: Benign prostatic hyperplasia (BPH) is a common chronic progressive disease resulting in urinary obstruction in aging men. It comes to more and more patients with massive BPH with the aging of society and extension of life expectancy. Objective: The aim of the study was to compare the clinical efficacy, safety, and complications between transurethral bipolar plasmakinetic enucleation of the prostate (PKEP) and transurethral resection of the prostate (TURP) in the treatment of massive BPH. Design and Setting: Patients with BPH were divided into the PKEP group and the TURP group randomly. Intraoperative blood loss (BL), operation time (OT), resected tissue weight (RTW), gland resection ratio (GRR), postoperative indwelling ureter time (IUT), bladder fistula time (BFT) and hospital stay time (HST), preoperative and postoperative serum sodium concentration (SSC), hemoglobin concentration (HGB), prostate weight (PW), postvoid residual (PVR), maximum urinary flow rate (Qmax), international prostate symptom score (IPSS), quality of life (QOL), International Index of Erectile Function (IIEF), and other complications were analyzed and compared respectively. Results: There was no statistical difference in preoperative IPSS, preoperative QOL score, preoperative PVR, preoperative Qmax, postoperative QOL score, postoperative PVR, postoperative Qmax, IPSS difference value (DV), Qmax DV, and PVR DV between the PKEP group and the TURP group (p > 0.05). OT, BL, IUT, BFT, HST, and postoperative IPSS in the PKEP group were significantly lower than that in the TURP group (p < 0.01). RTW and GRR in the PKEP group were significantly higher than that in the TURP group (p < 0.01). QOL DV in the PKEP group was higher than that in the TURP group (p < 0.05). There was statistical difference in SSC DV between the PKEP group and the TURP group (p < 0.05). There was significant statistical difference in postoperative PW, postoperative HGB, PW DV, and HGB DV between the PKEP group and the TURP group (p < 0.01). There was significant statistical difference in IPSS, QOL, PVR, and Qmax between postoperative value and preoperative value in both groups (p < 0.01). The incidence of transurethral resection syndrome, obturator nerve reflex, transient urinary incontinence, and retrograde ejaculation between the PKEP group and the TURP group has no statistical difference (p > 0.05). Capsule perforation, blood transfusion, secondary hemorrhage, bladder neck contracture, and urethral stricture in the PKEP group were lower than that in the TURP group (p < 0.05). Bladder spasm in the PKEP group was significantly lower than that in the TURP group (p < 0.01). There was no statistical difference in preoperative and postoperative IIEF-5, effective erectile frequency, telotism average tension, sustainable telotism average time, and sexual dissatisfaction between the PKEP group and the TURP group (p > 0.05). Conclusions: PKEP and TURP have similar clinical efficacy in the treatment of massive BPH. PKEP has advantages in shorter OT, less BL, more GRR, and fewer complications, but the long-term therapeutic effect of PKEP needs further follow-up.

1.
Chughtai
B
,
Forde
JC
,
Thomas
DD
,
Laor
L
,
Hossack
T
,
Woo
HH
,
Benign prostatic hyperplasia
.
Nat Rev Dis Primers
.
2016
;
2
:
16031
. .
2.
Kim
EH
,
Larson
JA
,
Andriole
GL
.
Management of benign prostatic hyperplasia
.
Annu Rev Med
.
2016
;
67
:
137
. .
3.
Namdarian
B
,
Willder
S
,
Steele
G
,
Leona
R
,
Grills
R
.
Establishment of a urology service in a developing country: an observational study of outcomes in transurethral prostate resection procedures in Vanuatu
.
Lancet
.
2015
;
385
(
Suppl 2
):
S26
. .
4.
Li
Z
,
Chen
P
,
Wang
J
,
Mao
Q
,
Xiang
H
,
Wang
X
,
The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: a systematic review and network meta-analysis
.
Medicine
.
2016
;
95
(
24
):
e3862
. .
5.
Zou
Z
,
Xu
A
,
Zheng
S
,
Chen
B
,
Xu
Y
,
Li
H
,
Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results
.
World J Urol
.
2018
;
36
(
7
):
1117
. .
6.
Gudmundsson
J
,
Sigurdsson
JK
,
Stefansdottir
L
,
Agnarsson
BA
,
Isaksson
HJ
,
Stefansson
OA
,
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA
.
Nat Commun
.
2018
;
9
(
1
):
4568
. .
7.
Cha
JY
,
Wee
J
,
Jung
J
,
Jang
Y
,
Lee
B
,
Hong
GS
,
Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia
.
Proc Natl Acad Sci U S A
.
2015
;
112
(
31
):
9722
. .
8.
Bosch
RJ
.
Pathogenesis of benign prostatic hyperplasia
.
Eur Urol
.
1991
;
20
(
Suppl 1
):
27
.
9.
Xu
D
,
Chen
P
,
Xiao
H
,
Wang
X
,
DiSanto
ME
,
Zhang
X
.
Upregulated interleukin 21 receptor enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia
.
Front Endocrinol
.
2019
;
10
:
4
. .
10.
Suskind
AM
,
Walter
LC
,
Zhao
S
,
Finlayson
E
.
Functional outcomes after transurethral resection of the prostate in nursing home residents
.
J Am Geriatr Soc
.
2017
;
65
(
4
):
699
. .
11.
Xu
P
,
Xu
A
,
Chen
B
,
Zheng
S
,
Xu
Y
,
Li
H
,
Bipolar transurethral enucleation and resection of the prostate: whether it is ready to supersede TURP?
Asian J Urol
.
2018
;
5
(
1
):
48
. .
12.
Wu
G
,
Hong
Z
,
Li
C
,
Bian
C
,
Huang
S
,
Wu
D
.
A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up
.
Lasers Med Sci
.
2016
;
31
(
4
):
599
. .
13.
Feng
L
,
Song
J
,
Zhang
D
,
Tian
Y
.
Evaluation of the learning curve for transurethral plasmakinetic enucleation and resection of prostate using a mentor-based approach
.
Int Braz J Urol
.
2017
;
43
(
2
):
245
. .
14.
Gilling
PJ
,
Aho
TF
,
Frampton
CM
,
King
CJ
,
Fraundorfer
MR
.
Holmium laser enucleation of the prostate: results at 6 years
.
Eur Urol
.
2008
;
53
(
4
):
744
. .
15.
Xu
H
,
Gu
M
,
Chen
Q
,
Chen
YB
,
Wang
Z
.
[Modified morcellation procedure in holmium laser enucleation of the prostate]
.
Zhonghua Nan Ke Xue
.
2016
;
22
(
11
):
991
.
16.
Luo
YH
,
Shen
JH
,
Guan
RY
,
Li
H
,
Wang
J
.
Plasmakinetic enucleation of the prostate vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: comparison of outcomes according to prostate size in 310 patients
.
Urology
.
2014
;
84
(
4
):
904
. .
17.
Liu
Z
,
Li
YW
,
Wu
WR
,
Lu
Q
.
Long-term clinical efficacy and safety profile of transurethral resection of prostate versus plasmakinetic resection of the prostate for benign prostatic hyperplasia
.
Urology
.
2017
;
103
:
198
. .
18.
Reich
O
,
Gratzke
C
,
Bachmann
A
,
Seitz
M
,
Schlenker
B
,
Hermanek
P
,
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients
.
J Urol
.
2008
;
180
(
1
):
246
. .
19.
Zhao
Z
,
Ma
W
,
Xuan
X
,
Ou
L
,
Liang
Y
,
Zeng
G
.
Impact of plasmakinetic enucleation of the prostate (PKEP) on sexual function: results of a prospective trial
.
J Sex Med
.
2012
;
9
(
5
):
1473
. .
20.
Peng
M
,
Yi
L
,
Wang
Y
.
Photoselective vaporization of the prostate vs plasmakinetic resection of the prostate: a randomized prospective trial with 12-month follow-up in Mainland China
.
Urology
.
2016
;
87
:
161
. .
21.
Hirik
E
,
Bozkurt
A
,
Karabakan
M
,
Aydemir
H
,
Aktas
BK
,
Nuhoglu
B
.
Safety and efficacy of bipolar versus monopolar transurethral resection of the prostate: a comparative study
.
Urol J
.
2015
;
12
(
6
):
2452
.
22.
Borchert
A
,
Leavitt
DA
.
A review of male sexual health and dysfunction following surgical treatment for benign prostatic hyperplasia and lower urinary tract symptoms
.
Curr Urol Rep
.
2018
;
19
(
8
):
66
. .
23.
Sun
F
,
Sun
X
,
Shi
Q
,
Zhai
Y
.
Transurethral procedures in the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis of effectiveness and complications
.
Medicine
.
2018
;
97
(
51
):
e13360
. .
24.
Gilling
P
,
Barber
N
,
Bidair
M
,
Anderson
P
,
Sutton
M
,
Aho
T
,
WATER: a double-blind, randomized, controlled trial of aquablation(R) vs transurethral resection of the prostate in benign prostatic hyperplasia
.
J Urol
.
2018
;
199
:
1252
.
25.
Liu
C
,
Zheng
S
,
Li
H
,
Xu
K
.
Transurethral enucleation and resection of prostate in patients with benign prostatic hyperplasia by plasma kinetics
.
J Urol
.
2010
;
184
(
6
):
2440
. .
26.
Chen
S
,
Zhu
L
,
Cai
J
,
Zheng
Z
,
Ge
R
,
Wu
M
,
Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years
.
Eur Urol
.
2014
;
66
(
2
):
284
. .
27.
Zhao
Z
,
Zeng
G
,
Zhong
W
,
Mai
Z
,
Zeng
S
,
Tao
X
.
A prospective, randomised trial comparing plasmakinetic enucleation to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: three-year follow-up results
.
Eur Urol
.
2010
;
58
(
5
):
752
. .
28.
Russo
GI
,
Regis
F
,
Spatafora
P
,
Frizzi
J
,
Urzì
D
,
Cimino
S
,
Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms (MIPS Study)
.
BJU Int
.
2018
;
121
:
799
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.